Sanofi's 'Miracle Spaceship' Docks at CIIE, Showcasing Five Innovative Product Debuts

On November 6, 2022, Sanofi, a global leader in innovative pharmaceuticals and healthcare, participated in the 5th China International Import Expo (CIIE). As a “perfect attendee” having participated for five consecutive years, and marking its 40th anniversary in China, Sanofi centered its presence on its corporate mission, “Chasing the miracles of science to bring life to life.” Boarding the “Miracle Spaceship” laden with numerous innovative achievements, the company conveyed its spirit of innovation and commitment to China to the world. At this prestigious event, Sanofi showcased strategic innovations across its full portfolio, including immunology and inflammation, rare diseases, vaccines, chronic diseases, and consumer healthcare. The company also featured the China debuts of five key products, joining hands with partners to embark on a new journey to support the Healthy China initiative over the next four decades.

“As one of the hallmarks of China’s high-level opening-up, the China International Import Expo (CIIE) has brought tremendous opportunities to numerous multinational corporations, including Sanofi. This year marks our fifth consecutive participation in the CIIE. We look forward to leveraging this important platform to showcase our innovative achievements and new mission, conveying our spirit of innovation and commitment to China to the world.”Sanofi Greater China President Shi Wangstated, “We place great emphasis on long-term, stable growth in the Chinese market. Moving forward, we will remain steadfast in our patient-centric approach, intensify our R&D and innovation efforts, collaborate with partners across all sectors, and never cease our pursuit of scientific breakthroughs, thereby contributing to the sustainable development of China’s local healthcare ecosystem.”

Sanofi China Leadership Team Officially Launches Sanofi’s 5th CIIE Participation

Sanofi has established its new corporate mission this year: “Pursuing the Miracles of Science, Illuminating the Brilliance of Life.” The booth design this year is centered around this theme, adopting the concept of the “Miracle Spaceship” to create areas including"Forty Years of Partnership in China," "Revitalizing the Brilliance of Life," and "Innovation-Driven Healthy China"Three themed exhibition zones, along with the “Miracle” cloud booth, showcase online and offline highlights of key milestones from the past four decades, efforts to create a better life for Chinese patients and employees, achievements in building a digital ecosystem, and the blueprint for future star innovative products.

For the fifth time at CIIE, Sanofi prominently showcased among its innovative exhibits5 Debut Innovative Products, including: three products in the fields of immuno-inflammation and rare diseases—Dupixent, with its new indication for moderate-to-severe atopic dermatitis expanded to include infants and young children^®(The only systemic therapy for atopic dermatitis covering the entire population), Nexviazyme makes its China debut^®*(New-generation enzyme replacement therapy for Pompe disease) and Cablivi^®*(the world’s first approved nanobody drug, and the first targeted therapy for acquired thrombotic thrombocytopenic purpura [aTTP]), among others; one preventive product—Beyfortus (nirsevimab), making its global debut^*(The world’s first and only long-acting monoclonal antibody for RSV prevention broadly applicable to the infant population); one product in the chronic disease sector—Soliqua™ (iGlarLixi*), an innovative combination therapy in diabetes developed specifically for Chinese patients.

During the exhibition, a special AD-themed art installation titled “A Life Trapped by Itch” was featured. Drawing from the real-life daily experiences of patients, it used immersive scenarios to illustrate the profound physical and psychological burdens faced by individuals with atopic dermatitis, aiming to raise societal awareness of this patient population and deepen public understanding of this prevalent disease.

AD Art Exhibition: A Life Trapped by Itch

In the realm of vaccine innovation, Sanofi Vaccines, in collaboration with Shenzhen Zhiliaoyun Technology Co., Ltd. and the Chinese Academy of Sciences, has jointly launched a new generation of smart unmanned vaccination pods. Inside the new-generation pod, recipients need only roll up their sleeves to expose the injection site; after automated disinfection by the machine, the injection is rapidly completed, with the entire process averaging just 35 seconds. Furthermore, the pod features full-environment standard cold-chain storage and automatic vaccine identification capabilities, ensuring traceability and secure storage of vaccines while achieving “zero-error” vaccine retrieval in vaccination scenarios.

Sanofi will also premiere a short educational film on cardiovascular disease and announce the launch of “Li Guan’ai,” a WeChat Channels account dedicated to cardiovascular health education. By collaborating with social media influencers and the medical community, Sanofi aims to create innovative educational content and approaches, jointly shaping new trends in health communication.

As a "pioneer" in the digitalization of the healthcare sector, Sanofi is driving new digital advancements. At its exhibition booth, the company showcased a digital ecosystem matrix comprising eight innovative projects. Focusing on rare diseases, cardiovascular diseases, and atopic dermatitis, this digital framework covers the entire patient journey—from early screening, diagnosis, and treatment to daily disease management.

The “spillover effect” generated by the China International Import Expo (CIIE) has significantly benefited Sanofi. For instance, following its debut at the first CIIE, Dupixent®—which expanded its indication for moderate-to-severe atopic dermatitis to include infants and young children—has demonstrated remarkable “China speed”: it received regulatory approval in 2020, two years ahead of schedule; achieved market supply just 25 days after approval; was included in the National Reimbursement Drug List within five months of launch; gained approval for adolescent indications in 2021; and this year, secured approval for children aged six years and older as well as adults, becoming the only targeted biologic agent currently approved in China for the treatment of moderate-to-severe atopic dermatitis across children, adolescents, and adults.

In light of this, Sanofi remains firmly committed to its long-term dedication to China, leveraging its global R&D capabilities and local insights to engage more actively in China’s innovation ecosystem. At this year’s China International Import Expo (CIIE), Sanofi will announce the signing of strategic cooperation agreements with partners including the Shenzhen Center for Disease Control and Prevention, Health Cloud, and China Resources Sanjiu, working together to build a localized innovation ecosystem. Notably, Sanofi and its “long-standing partner” JD Health will announce a further upgrade of their collaboration in the internet healthcare sector. The two parties will expand their existing cooperation from the field of chronic diseases to atopic dermatitis (AD), by creating the first one-stop online platform for comprehensive AD disease management, thereby addressing the more diverse health needs of atopic dermatitis patients in the digital era.

Sanofi’s four-decade journey in China is a vibrant chapter of shared growth with the nation’s healthcare era. The “Miracle Ship” is poised to embark on its next 40-year voyage, continuing to paint a new Chinese vision that places “people’s health above all.” Guided by innovative insights into industry development and fueled by an unwavering passion to explore scientific breakthroughs for patients, Sanofi remains steadfast in its commitment to China. Joining hands with like-minded partners, Sanofi aims to lead transformative change in China’s healthcare sector, revolutionize medical practices, and make positive contributions to building a Healthy China.

Sanofi's Booth at the 5th China International Import Expo

Sanofi is a global leader in innovative healthcare, driven by its mission to “chase the miracles of science and improve people’s lives.” As one of the first multinational corporations to enter China after the launch of the country’s reform and opening-up policy, Sanofi established its office in China in 1982. Currently, it operates 12 offices with diverse models, three manufacturing sites, four R&D centers, and one digital innovation hub. Its diversified business portfolio spans pharmaceuticals, human vaccines, and consumer healthcare. Walking hand in hand with China, Sanofi is committed to accelerating the introduction of innovative medicines and vaccines into the Chinese market, continuously transforming medical practices to benefit more Chinese citizens, while also creating a better life for its partners, communities, and employees.

Sanofi is a global leader in innovative healthcare. Our mission is to pursue the miracles of science and improve people’s lives. With a presence in over 100 countries worldwide, Sanofi is committed to transforming medical practice and turning the impossible into the possible. We provide life-changing healthcare solutions and vaccines that prevent life-threatening diseases to people around the world, while placing sustainability and social responsibility at the core of our ambitious strategy.

* This product/indication has not yet been approved for marketing in China and is limited to on-site display at the 2022 China International Import Expo.